Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00887198
Registration number
NCT00887198
Ethics application status
Date submitted
18/04/2009
Date registered
23/04/2009
Date last updated
25/06/2018
Titles & IDs
Public title
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Query!
Scientific title
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Query!
Secondary ID [1]
0
0
COU-AA-302
Query!
Secondary ID [2]
0
0
CR016927
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Prostate Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Prostate
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Abiraterone acetate
Treatment: Drugs - Placebo
Treatment: Drugs - Prednisone
Placebo Comparator: Placebo + prednisone - Placebo plus prednisone
Experimental: Abiraterone + prednisone - Abiraterone acetate plus prednisone
Treatment: Drugs: Abiraterone acetate
1000 mg per day (4 x 250-mg tablets) taken orally.
Treatment: Drugs: Placebo
4 placebo tablets per day taken orally.
Treatment: Drugs: Prednisone
5 mg tablet orally twice daily.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival
Query!
Assessment method [1]
0
0
Overall survival is defined as the time from randomization to date of death from any cause.
Query!
Timepoint [1]
0
0
From randomization (Day 1) up to end of study (Month 60)
Query!
Primary outcome [2]
0
0
Radiographic Progression-free Survival (rPFS)
Query!
Assessment method [2]
0
0
The rPFS was defined as the time from randomization to the occurrence of one of the following: 1) a participant was considered to have progressed by bone scan if - a) the first bone scan with greater than or equal to (>=) 2 new lesions compared to baseline was observed in less than (<) 12 weeks from randomization and was confirmed by a second bone scan taken >=6 weeks later showing >=2 additional new lesions (a total of >=4 new lesions compared to baseline), b) the first bone scan with >=2 new lesions compared to baseline was observed in >=12 weeks from randomization and the new lesions were verified on the next bone scan >=6 weeks later (a total of >=2 new lesions compared to baseline); 2) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI); 3) death from any cause.
Query!
Timepoint [2]
0
0
From randomization (Day 1) up to first radiographic progression or cutoff date (Month 18)
Query!
Secondary outcome [1]
0
0
Time to Opiate Use for Prostate Cancer Pain
Query!
Assessment method [1]
0
0
The time interval from the date of randomization to the date of opiate use for cancer pain. Participants who have no opiate use at the time of analysis were censored at the last known date of no opiate use for cancer pain. Participants with no assessment were censored at the date of randomization.
Query!
Timepoint [1]
0
0
From randomization (Day 1) up to first opiate use or end of study (Month 60)
Query!
Secondary outcome [2]
0
0
Time to Initiation of Cytotoxic Chemotherapy
Query!
Assessment method [2]
0
0
The time interval from the date of randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer. Participants who had no cytotoxic chemotherapy administration at the time of analysis were censored at the last known date when no cytotoxic chemotherapy was administered. Participants with no assessment were censored at the date of randomization.
Query!
Timepoint [2]
0
0
From randomization (Day 1) up to initiation of cytotoxic chemotherapy or cutoff date (Month 18)
Query!
Secondary outcome [3]
0
0
Time to Deterioration in Eastern Cooperative Oncology Group (ECOG) Performance Score by >=1 Point
Query!
Assessment method [3]
0
0
The time interval from the date of randomization to the first date at which there was at least a 1 grade change (worsening) in the ECOG performance status grade. Participants who had no deterioration in ECOG performance status grade at the time of the analysis were censored at the last known date of no deterioration. ECOG is a 5-point scale, where 0=Fully active, 1=Ambulatory, carry out work of sedentary nature, 2=Ambulatory, capable of all self-care, 3=Capable of limited self-care, confined to bed or chair more than 50% of waking hours, 4=Completely disabled, no self-care, totally confined to bed or chair, 5=Dead. Participants with no assessment were censored at the date of randomization.
Query!
Timepoint [3]
0
0
From randomization (Day 1) up to first radiographic progression or cutoff date (Month 18)
Query!
Secondary outcome [4]
0
0
Time to Prostate-specific Antigen (PSA) Progression
Query!
Assessment method [4]
0
0
The time interval from the date of randomization to the date of PSA progression as defined in the protocol-specific prostate cancer Working Group 2 (PCWG2) criteria. A participant was considered to have a PSA progression if the PSA level had a 25 percent (%) or greater increase from nadir and an absolute increase of 2 nanogram/milliliter ((ng/mL) or more, which is confirmed by a second value obtained in 3 or more weeks. Participants who had no PSA progression at the time of the analysis were censored at the last known date of no PSA progression. Participants with no on-study PSA assessment or no baseline PSA assessment were censored at the date of randomization.
Query!
Timepoint [4]
0
0
From randomization (Day 1) up to date of PSA progerssion or cutoff date (Month 18)
Query!
Secondary outcome [5]
0
0
Number of Participants With Treatment Emergent Adverse Events
Query!
Assessment method [5]
0
0
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state.
Query!
Timepoint [5]
0
0
From first dose of study drug up to 30 days after the last dose of study drug
Query!
Secondary outcome [6]
0
0
Mean Plasma Concentrations of Abiraterone
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Up to Cycle 5, Day 1
Query!
Secondary outcome [7]
0
0
Maximum Plasma Concentrations of Abiraterone
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Up to Cycle 5, Day 1
Query!
Secondary outcome [8]
0
0
Area Under the Plasma Concentration-time Curve From Time 0 to Time the Last Quantifiable Concentration of Abiraterone (AUC[0-infinity])
Query!
Assessment method [8]
0
0
The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.
Query!
Timepoint [8]
0
0
Up to Cycle 5, Day 1
Query!
Secondary outcome [9]
0
0
Elimination Half-Life (t1/2)
Query!
Assessment method [9]
0
0
The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).
Query!
Timepoint [9]
0
0
Up to Cycle 5, Day 1
Query!
Eligibility
Key inclusion criteria
- Metastatic castration-resistant prostate cancer (CRPC)
- Previous anti-androgen therapy and progression after withdrawal
- ECOG performance status of either 0 or 1
- Medical or surgical castration with testosterone less than 50 ng/dL
- Life expectancy of at least 6 months
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Prior cytotoxic chemotherapy or biologic therapy for CRPC
- Prior ketoconazole for prostate cancer
- Known brain metastasis or visceral organ metastasis
- Use of opiate analgesics for cancer-related pain, including codeine and
dextropropoxyphene, currently or anytime within 4 weeks of Cycle 1 Day 1
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
28/04/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
25/05/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1088
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Adelaide
Query!
Recruitment hospital [2]
0
0
- Camperdown
Query!
Recruitment hospital [3]
0
0
- Footscray
Query!
Recruitment hospital [4]
0
0
- Frankston
Query!
Recruitment hospital [5]
0
0
- Garran
Query!
Recruitment hospital [6]
0
0
- Geelong
Query!
Recruitment hospital [7]
0
0
- Heidelberg
Query!
Recruitment hospital [8]
0
0
- Herston
Query!
Recruitment hospital [9]
0
0
- Hornsby
Query!
Recruitment hospital [10]
0
0
- Kogarah
Query!
Recruitment hospital [11]
0
0
- Kurralta Park
Query!
Recruitment hospital [12]
0
0
- Lismore
Query!
Recruitment hospital [13]
0
0
- Liverpool
Query!
Recruitment hospital [14]
0
0
- Malvern
Query!
Recruitment hospital [15]
0
0
- Parkville
Query!
Recruitment hospital [16]
0
0
- Perth
Query!
Recruitment hospital [17]
0
0
- South Brisbane
Query!
Recruitment hospital [18]
0
0
- Southport
Query!
Recruitment hospital [19]
0
0
- Subiaco
Query!
Recruitment postcode(s) [1]
0
0
- Adelaide
Query!
Recruitment postcode(s) [2]
0
0
- Camperdown
Query!
Recruitment postcode(s) [3]
0
0
- Footscray
Query!
Recruitment postcode(s) [4]
0
0
- Frankston
Query!
Recruitment postcode(s) [5]
0
0
- Garran
Query!
Recruitment postcode(s) [6]
0
0
- Geelong
Query!
Recruitment postcode(s) [7]
0
0
- Heidelberg
Query!
Recruitment postcode(s) [8]
0
0
- Herston
Query!
Recruitment postcode(s) [9]
0
0
- Hornsby
Query!
Recruitment postcode(s) [10]
0
0
- Kogarah
Query!
Recruitment postcode(s) [11]
0
0
- Kurralta Park
Query!
Recruitment postcode(s) [12]
0
0
- Lismore
Query!
Recruitment postcode(s) [13]
0
0
- Liverpool
Query!
Recruitment postcode(s) [14]
0
0
- Malvern
Query!
Recruitment postcode(s) [15]
0
0
- Parkville
Query!
Recruitment postcode(s) [16]
0
0
- Perth
Query!
Recruitment postcode(s) [17]
0
0
- South Brisbane
Query!
Recruitment postcode(s) [18]
0
0
- Southport
Query!
Recruitment postcode(s) [19]
0
0
- Subiaco
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Hawaii
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Kansas
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Louisiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Maryland
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Massachusetts
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Michigan
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Minnesota
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Missouri
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Montana
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Nebraska
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Nevada
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
New York
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
North Carolina
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Ohio
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Oregon
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Pennsylvania
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
South Carolina
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Tennessee
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Texas
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Virginia
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Washington
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Wisconsin
Query!
Country [30]
0
0
Belgium
Query!
State/province [30]
0
0
Aalst
Query!
Country [31]
0
0
Belgium
Query!
State/province [31]
0
0
Antwerpen
Query!
Country [32]
0
0
Belgium
Query!
State/province [32]
0
0
Gent
Query!
Country [33]
0
0
Belgium
Query!
State/province [33]
0
0
Hasselt
Query!
Country [34]
0
0
Belgium
Query!
State/province [34]
0
0
Leuven Belgie
Query!
Country [35]
0
0
Belgium
Query!
State/province [35]
0
0
Roeselare
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Alberta
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
British Columbia
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
Ontario
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
Quebec
Query!
Country [40]
0
0
Canada
Query!
State/province [40]
0
0
London
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Caen
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Clichy
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Dijon Cedex
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
La Roche Sur Yon
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Lyon Cedex 03
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Lyon
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Montpellier
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Paris Cedex 15
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Tours, Cedex 9
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Villejuif
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Aachen
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Berlin
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Braunschweig
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Dresden
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Düsseldorf
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Hamburg
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Hannover
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Homburg
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Kempen
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Leipzig
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Muenchen
Query!
Country [62]
0
0
Germany
Query!
State/province [62]
0
0
Münster
Query!
Country [63]
0
0
Germany
Query!
State/province [63]
0
0
Wuppertal
Query!
Country [64]
0
0
Greece
Query!
State/province [64]
0
0
Athens
Query!
Country [65]
0
0
Greece
Query!
State/province [65]
0
0
Larisa
Query!
Country [66]
0
0
Netherlands
Query!
State/province [66]
0
0
Amsterdam
Query!
Country [67]
0
0
Netherlands
Query!
State/province [67]
0
0
Heerlen
Query!
Country [68]
0
0
Netherlands
Query!
State/province [68]
0
0
Nijmegen
Query!
Country [69]
0
0
Netherlands
Query!
State/province [69]
0
0
Rotterdam
Query!
Country [70]
0
0
Spain
Query!
State/province [70]
0
0
Barcelona
Query!
Country [71]
0
0
Spain
Query!
State/province [71]
0
0
Coruña
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
Madrid
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
Oviedo
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Santander N/A
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Santiago De Compostela
Query!
Country [76]
0
0
Sweden
Query!
State/province [76]
0
0
Göteborg
Query!
Country [77]
0
0
Sweden
Query!
State/province [77]
0
0
Malmö N/A
Query!
Country [78]
0
0
Sweden
Query!
State/province [78]
0
0
Stockholm
Query!
Country [79]
0
0
Sweden
Query!
State/province [79]
0
0
Uppsala
Query!
Country [80]
0
0
Sweden
Query!
State/province [80]
0
0
Växjö
Query!
Country [81]
0
0
United Kingdom
Query!
State/province [81]
0
0
Birmingham
Query!
Country [82]
0
0
United Kingdom
Query!
State/province [82]
0
0
Cambridge
Query!
Country [83]
0
0
United Kingdom
Query!
State/province [83]
0
0
Glasgow
Query!
Country [84]
0
0
United Kingdom
Query!
State/province [84]
0
0
Leeds
Query!
Country [85]
0
0
United Kingdom
Query!
State/province [85]
0
0
London
Query!
Country [86]
0
0
United Kingdom
Query!
State/province [86]
0
0
Manchester
Query!
Country [87]
0
0
United Kingdom
Query!
State/province [87]
0
0
Newcastle Upon Tyne
Query!
Country [88]
0
0
United Kingdom
Query!
State/province [88]
0
0
Oxford
Query!
Country [89]
0
0
United Kingdom
Query!
State/province [89]
0
0
Sutton
Query!
Country [90]
0
0
United Kingdom
Query!
State/province [90]
0
0
Whitchurch
Query!
Country [91]
0
0
United Kingdom
Query!
State/province [91]
0
0
Wirral
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Janssen Research & Development, LLC
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus
prednisone with placebo plus prednisone in asymptomatic or mildly symptomatic patients with
metastatic castration-resistant prostate cancer (CRPC).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00887198
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Janssen Research & Development, LLC Clinical Trial
Query!
Address
0
0
Janssen Research & Development, LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00887198
Download to PDF